NDC product
clindamycin palmitate hydrochloride
NDC 23155-603 · Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
Key facts
| Product NDC | 23155-603 |
|---|---|
| Proprietary name | clindamycin palmitate hydrochloride |
| Nonproprietary name | clindamycin palmitate hydrochloride |
| Substances | CLINDAMYCIN PALMITATE HYDROCHLORIDE |
| Dosage form | GRANULE, FOR SOLUTION |
| Route | ORAL |
| Labeler | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA207047 |
| Pharmacologic classes | Decreased Sebaceous Gland Activity [PE], Lincosamide Antibacterial [EPC], Lincosamides [CS], Neuromuscular Blockade [PE] |
| Marketing start | May 11, 2018 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: